Skip to main content
Premium Trial:

Request an Annual Quote

Tempus Closes $100M Series G Round

NEW YORK – Tempus said Friday that it has closed a $100 million Series G round of funding, bringing the company's total capital raised since its founding in 2015 to $620 million and its valuation to $5 billion. Investors included Baillie Gifford, Franklin Templeton, NEA, and Novo Holdings, plus funds and accounts managed by T. Rowe Price.

Last May, Tempus raised $200 million in a Series F round from the same investors, as well as Revolution Growth. 

Tempus, a sequencing, informatics, and precision medicine company based in Chicago, said it would apply the funding to continue its expansion into other disease areas, such as diabetes, depression, and cardiology, from its original focus on oncology.  

"As a leader in bringing the power and promise of artificial intelligence to healthcare, we're mindful of the size and scope of the opportunity in front of us," Founder and CEO Eric Lefkofsky said in a statement. "The latest fundraising will enhance our ability to forward-invest in new disease areas and geographies."